Baxter International Inc. has announced publication of the results of two health economic analyses in the Journal of Medical Economics supporting Floseal Hemostatic Matrix as a cost-effective tool for controlling bleeding during cardiac and spinal surgeries that may contribute to significant cost savings for hospitals. The analyses are based on previously published retrospective studies of a large U.S. hospital billing database that observed fewer complications in surgeries that used Floseal compared to another flowable hemostatic matrix.

Complications during surgery, such as the need for blood transfusions or longer times in the operating room, can increase costs for a hospital and impact patient care. In the cardiac surgery analysis, researchers calculated the potential cost savings of using Floseal when compared to Surgiflo to be $1.5 million annually for an average U.S. hospital, assuming Floseal use would result in improved clinical outcomes similar to those observed in the prior retrospective study. Savings would come from fewer major and minor complications, surgical revisions, blood product transfusions and hours of operating time.

“Based on the real-world outcomes observed in the earlier study, this new health economics analysis identifies a substantial opportunity for hospitals to realize potential cost savings on cardiac surgery operations, which are among the surgical specialties the most susceptible to the occurrence of intra-operative and post-operative bleeding,” said Domenico Calcaterra, M.D., Ph.D., Minneapolis Heart Institute at Abbott Northwestern Hospital, Minn. Calcaterra co-authored the original retrospective study.

In the second study, researchers identified potential cost savings of $151 per major and $574 per severe spinal surgery when compared to Surgiflo for hospitals with average surgical volume by improving surgical outcomes and efficiencies. The savings would come from a combination of resource use factors, including shorter operative room time, a lower blood transfusion rate and lower product volume use.

In addition to reducing a hospital’s costs, addressing bleeding effectively and quickly is critical to avoiding major and minor complications for patients. Floseal is an indicated and approved adjunct hemostatic agent proven effective in a wide-range of bleeding scenarios.